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Abstract
The current treatment approach for type 1 diabetes is based on daily insulin injections, combined with blood
glucose monitoring. However, administration of exogenous insulin fails to mimic the physiological activity of the
islet, therefore diabetes often progresses with the development of serious complications such as kidney failure,
retinopathy and vascular disease. Whole pancreas transplantation is associated with risks of major invasive surgery
along with side effects of immunosuppressive therapy to avoid organ rejection. Replacement of pancreatic
beta-cells would represent an ideal treatment that could overcome the above mentioned therapeutic hurdles. In
this context, transplantation of islets of Langerhans is considered a less invasive procedure although long-term
outcomes showed that only 10 % of the patients remained insulin independent five years after the transplant.
Moreover, due to shortage of organs and the inability of islet to be expanded ex vivo, this therapy can be offered
to a very limited number of patients. Over the past decade, cellular therapies have emerged as the new frontier of
treatment of several diseases. Furthermore the advent of stem cells as renewable source of cell-substitutes to
replenish the beta cell population, has blurred the hype on islet transplantation. Breakthrough cellular approaches
aim to generate stem-cell-derived insulin producing cells, which could make diabetes cellular therapy available to
millions. However, to date, stem cell therapy for diabetes is still in its early experimental stages. This review
describes the most reliable sources of stem cells that have been developed to produce insulin and their most
relevant experimental applications for the cure of diabetes.
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Background
The therapeutic approach for type 1 diabetes (T1D) is
based on daily insulin injections, combined with blood glu-
cose monitoring, healthy lifestyle and diet. Administration
of exogenous insulin fails to mimic the physiological activity
of the islet and disease progression may lead to the devel-
opment of serious complications such as kidney failure, ret-
inopathies and vascular diseases.
Replacement of pancreatic beta-cells represents an
ideal treatment that could overcome the above men-
tioned therapeutic hurdles. Whole pancreas transplant-
ation was performed for the first time in 1966 by Kelly
and co-workers [1]. It is currently performed in associ-
ation with kidney transplantation in adult patients with
both renal failure and T1D. Although the positive 1st
year survival rates (77 %), the pancreas transplant is as-
sociated with the risks of any major invasive surgery
along with the side effects of immunosuppressive ther-
apy to avoid organ rejection.
In this context transplantation of islets of Langerhans is a
less invasive procedure: after the enzymatic and mechanic
isolation from the deceased donor’s organ, islets cells are
purified and injected into the recipient’s liver via the portal
vein, where they rapidly engraft and re-vascularize. Pro-
gresses in islet isolation protocols and immunosuppression
therapy allowed restoration of normoglycemia in patients
who received islets from multiple donors. The “Edmonton
Protocol” is a milestone in this field and it is internationally
considered the best procedure to explore feasibility and re-
producibility of islet transplantation. Patients affected by
T1D underwent islet transplantation in conjunction with a
glucocorticoid-free immunosuppressive regimen consisting
of sirolimus, tacrolimus,and daclizumab with a good
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outcome at 12months of follow-up [2]. Although this in-
novative therapeutic approach was initially shown to be
successful, long-term outcomes depicted a different sce-
nario as about 10 % of the patients remained insulin inde-
pendent five years after the transplant, although this is
variable from a study to another. An international, multi-
centre trial conducted in 9 international sites and involving
36 patients with T1D, showed that 44 % achieved an insulin
independence with adequate glycaemic control 1 year after
the final transplantation (5 of them for 2 years), 28 % had
partial function, and 28 % had complete graft loss 1 year
after the final transplantation [3]. Brennan et al. reported
the long-term (12 years) follow-up of the efficacy and safety
of the first 7 islet transplantation in type 1 diabetic subjects.
All seven subjects demonstrated continued islet function
longer than a decade from the time of first islet transplant-
ation. One subject remained insulin independent without
the need for diabetic medications or supplemental trans-
plants. At trial completion, five subjects were receiving in-
sulin and two remained insulin independent, although one
was treated with liraglutide. No patients experienced severe
hypoglycaemia, opportunistic infection, or lymphoma [4].
Recently, long term follow up of two patients treated with
Islet transplant according to the Edmond protocol in 2001
were reported as insulin-independent for two years [5],
while the all the 10 patients described by Qui et al. in 2014
achieved an insulin independence after 1-3 transplants and
at 5 years of follow-up, and 6 of them were free of exogen-
ous insulin [6].
Although the Islet transplantation according to the
Edmond Protocol showed good results in terms of
safety, due to shortage of organs and inability of islet to
be expanded ex vivo, this therapy can be offered to a
very limited number of patients only [7]. However the
Islet Transplant continues to be matter of interesting
new studies, seen the recent results published by
Berman et al. aiming to develope a clinically applicable
protocol for extrahepatic transplantation of pancreatic
islets. The potency of islets implanted onto the omen-
tum, using an in situ–generated adherent, resorbable
plasma-thrombin biologic scaffold, was evaluated in dia-
betic animal models. An improved metabolic function
and preservation of islet cytoarchitecture was found and
long-term nonfasting normoglycemia and adequate glu-
cose clearance were achieved in both intrahepatic and
intraomental sites in rats [8]. New promising results are
also available on the protection that antiaging glycopep-
tide may offer to the Human Islets against Tacrolimus-
Related injury facilitationg the engraftment in animal
models [9].
Moreover, recent data were presented on the out-
comes of Pancreas Transplantation procedure after Islet
Transplantation failure (PAI) and vice-versa (IAP). Al-
though only a very limited number of patients received
these procedure, metabolic outcomes seems promitting,
specially in PAI [10]. The potential for long-term bank-
ing of human islets for research, was also recently de-
scribed. which could enable the use of tissue from a
large number of donors with future technologies [11].
As described, despite Islet and Pancreas transplant is an
important field in T1D treatment, over the past decade
cellular therapies have emerged as the new frontier for
the treatment of various lethal diseases and the advent
of stem cells as a renewable source of cell-substitutes, to
replenish the beta cell population, has blurred the hype
on islet transplantation. Breakthrough cellular ap-
proaches aim to generate stem cell derived insulin pro-
ducing cells, which could make diabetes cellular therapy
available to millions. However, to date, stem cell therapy
for diabetes is still in its early, yet promising, experimen-
tal stages.
Stem cells: proprieties and classification
Stem cells are characterized by two key features: (i) as
unspecialized cells they can divide and renew themselves
for long periods without differentiating in other cell
types, and (ii) they present the potential to develop into
many specialized cell types, under certain physiologic or
experimental conditions. Such process can be induced
by different signals, either internal, as genes expression,
or external, as physical contact, chemical secretions or
micro-environmental molecules. The induction leads to
cell specialization through the restriction and expression
of key genes.
Stem cells can be classified in different levels by their
plasticity, which is the ability to differentiate into the to-
tality or just a part of cell lineages. The zygote, resulting
by gametes fusion, represents a totipotent cell type, since
it gives rise to both embryo and placental trophoblast.
After four days of mitotic divisions, the zygote grows
into a group of cells referred to as blastocyst. Embryonic
stem cells (ESCs) deriving from the inner cell mass of
the blastocyst are pluripotent, because of their ability to
develop into the three germ layers but not into extraem-
bryonic tissues. ESCs were first derived from mouse em-
bryos [12] while in 1998 ESCs were isolated and
cultured from human blastocysts. The first transplants
of human ESCs in immune-deficient mice revealed an
additional peculiarity of pluripotent stem cells: the cap-
acity to generate teratomas composed of tissues from all
lineages. In contrast, adult stem cells, identified in vari-
ous organs and tissues, can be multipotent, showing the
potential to differentiate into multiple cell lineages, or
unipotent, when they retain a restricted ability to differ-
entiate [13]. Because of their peculiarities, stem cells are
considered the most promising candidates for future
therapeutic approaches of T1D and other degenerative
diseases. The aim of regenerative medicine for diabetes
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is to develop a renewable and safe source of stem cells
to replenish the damaged cells, providing the patients
with a long term source of insulin producing cells.
Stem cell approaches to restore insulin production
Adult stem cells: endodermic cells from pancreas and liver
Adult stem cells are undifferentiated cells showing the
potential to self-renew and differentiate into one or few
specific cell lineages of the tissue in which they are
found or “neighbour” tissues, in order to maintain and
repair the organ of origin. In situation of serious dam-
ages, various adult stem cell types can be recruited at
distance to repair injured areas. For these reasons, adult
stem cells are considered a suitable source for a wide
range of cell therapy applications, due to their ability to
differentiate in vivo, or to expand and differentiate
in vitro their progeny [14].
Reprogramming pancreatic adult stem cells
Pancreatic ducts, exocrine pancreas and islet of Langerhans
are proposed as sources of pancreatic stem/progenitor cells.
Although their nature and even their existence were ini-
tially subject of controversy in the field of beta-cell replace-
ment for diabetes [15], pancreatic resident adult stem cells
have been successfully differentiated into islet-like cells.
Studies on human pancreatic duct cells have shown their
ability to both proliferate in vitro and differentiate into in-
sulin producing cells [16, 17]. Other studies on pancreatic
resident adult stem cells describe how, after partial pancrea-
tectomy in diabetic mice, ductal progenitors are capable of
generating mature ductal epithelial cells. The proliferation
and differentiation of pancreatic progenitor cells, located in
the pancreatic ductal epithelium, might be involved in this
process. This hypothesis is suggested by the observation
that, after pancreatectomy, proliferation starts from the
main ducts followed by small ducts, until newly formed is-
lets appear at the periphery of ductules at the final stage of
regeneration [18–20]. Further experiments on human pan-
creatic duct cells have confirmed the outcomes from animal
models. In particular external stimuli, such as extracellular
matrix, enhance the expansion of ductal tissue and the dif-
ferentiation to islet-like structures along with the produc-
tion of insulin [21–23]. Moreover ductal cells after
differentiation are able to re-express the key transcription
factor IPF-1/PDX1 (insulin promoter facto-1/pancreas and
duodenal homebox-1) [24], which plays a key role in pan-
creas development.
Attempts at producing islet cells from acinar cells
were performed by Zhou et al. on rodent models. Their
studies have provided direct evidence that insulin secret-
ing cells can be generated in vitro from re-programming
of differentiated cells with exocrine functions such as
amylase/elastase-expressing pancreatic acinar cells and
non-endocrine epithelial cells, this latter resulting from
the remaining fraction after islet isolation [25].
Human pancreatic islets also contain an unrecognized
distinct population of cells that expresses the neural
stem cell-specific marker nestin. These promising
nestin-positive cells isolated from adult pancreas of ro-
dents and human, retain some proliferative capacity and
can differentiate ex vivo into pancreatic exocrine and
endocrine phenotypes [26].
Trans-differentiation of endodermic cells from liver
Liver and small intestine cells share the same lineage
origin of pancreatic cells. Therefore, both have been
tested as replacement insulin producing cells for dia-
betes cellular therapy [27–33].
To date, most of the approaches are focused on liver
as a promising abundant source for the generation of
insulin producing cells. Liver and pancreas cells, in ver-
tebrates, derive from the same indistinct pool of pro-
genitor stem cells resident in the extra-hepatic biliary
tree [34] and differentiate into hepatic and pancreatic
definitive tissues after chemical signals secreted by the
developing heart. [35–39] The discovery of mechanisms
for glucose sensing and signal transduction [40, 41] in
liver triggered the first cell trans-differentiation assays to
obtain insulin producing cells from hepatocytes. Several
groups successfully transdifferentiated hepatic cells into
insulin producing cells in rat models using adenovirus-
mediated gene transfer approaches to insert PDX1 alone
or in combination with NeuroD and MafA genes [42–45].
Despite the positive outcomes of these approaches, the
clinical translation of methods to the human is not applic-
able because of the safety issues raised by the use of
adenovirus. Furthermore, in vitro trans-differentiation led
to hybrid hepatocyte-beta cell phenotype incapable of
adjusting insulin levels according to variable glucose con-
centrations. Therefore, in the years to come further evalu-
ations are required to make liver cells a concrete and
viable source for beta cell replacement [46].
Adult stem cells: haemopoietic, mesenchymal cells and
pancreatic resident mesenchymal cells
The role of haemopoietic stem cells
Haemopoietic stem cells are situated in stem cell niches
like bone marrow or umbilical cord blood and differ from
mesenchymal cells, which are distributed in the entire
body and can generate fibroblast, adipocyte, chondrocyte
along with other connective cells [47]. Haemopoietic stem
cells are primarily used to treat immune-related disorders
because of their ability to encourage and stimulate vascu-
lar regeneration rather than an effective differentiation
into insulin producing cells. Voltarelli et al. have described
the attempt of resetting the immunological conditions of
diabetes by autologous transplantation of hematopoietic
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bone marrow-derived stem cells, after high doses of im-
munosuppressive drugs. Results have shown that their at-
tempt increased beta-cell function and prolonged insulin
independence in the majority of the patients, increasing
C-peptide levels and reducing hemoglobin A1c. However,
the exact mechanism of action of autologous transplant-
ation of bone marrow-derived stem cells in autoimmune
disorders is not yet fully understood [48]. Other groups
have injected hematopoietic bone marrow stem cells dir-
ectly into pancreatic tissue of patients with type 2 dia-
betes, in combination with hyperbaric oxygen treatment.
Such procedures have obtained promising outcomes, re-
ducing insulin requirements and improving glycaemic
control [49].
Mesenchymal stem cells
Ubiquitous mesenchymal stem cells (MSCs) can be iso-
lated from various tissues like umbilical cord, bone mar-
row, adipose tissue and placental tissues. However, to be
considered as MSCs, they must meet specific require-
ments such as adherence to plastic, differentiation abilities
towards bone, cartilage and fat lineage, presence/absence
of peculiar surface markers. Some MSCs also express
stemness markers of pluripotency like OCT4 and Nanog
[50]. Moreover, MSCs are characterized by high expansion
potential and no tumorigenic risks [47–51]. MSC have
shown, both in vitro and in vivo, a strong immunomodula-
tory activity which may help avoiding post-transplant re-
jection. Immunomodulation is mediated by different
mechanisms: secretions of soluble factors (e.g. prostaglan-
din E2 and IL-10), pathways activated by direct contact
with T-cell or interaction with dendritic cells [52]. Suc-
cessful studies on human MSC differentiated into insulin
producing cells were reported by Wu XH et al. [53] who
demonstrated the capacity of bone marrow mesenchymal
stem cells (BM-MSCs) to transdifferentiate in vitro into
islet-like cells and transplanted the cells into
streptozotocin-induced diabetic rat. Few years later in a
similar attempt, Phadnis SM et al. failed to accomplish a
sufficient in vitro differentiation of BM-MSC, while
achieved the amelioration of glycemia after injection of
immature cells in diabetic mice, showing that pre-induced
BM- MSCs (in vitro) completed their maturation into
endocrine pancreatic lineage and insulin producing cells
in vivo [54]. Other studies describe protocols for gener-
ation of glucose-responsive insulin-producing islet-like
clusters from accessible and abundant tissues like human
adipose tissue (AD- MSCs) [55, 56]; from Wharton’s jelly
[57],(WJ- MSCs), amniotic fluid (AF-MSCs) [58] and um-
bilical cord blood (UCB-MSC) [59]. Seeberg et al. have
proposed to use mesenchymal stem cells from pancreas to
produce beta-like cells, hypothesizing that the pancreatic
origin would ease the induction process. Data have shown
that MSCs isolated from adult human exocrine pancreatic
tissue express the same cell surface antigens of MSCs de-
rived from bone marrow, adipose tissue and umbilical
cord blood, and the same ability to differentiate into
mesodermic and endodermic cell lineages. Using a step-
wise differentiation protocol they generated cells retaining
a gene expression pattern (PDX1, Pax4 and ngn3) typical
of beta cells [60–62]. Recently, it was also showed by Cal
et al. the safety and the moderate improvement of meta-
bolic effects on insulin secretion of umbilical cord (UC)
MSCs plus autologous bone marrow mononuclear cell
(aBM-MNC) stem cell transplantation (SCT) without im-
munotherapy in established type 1 diabetes (T1D) [63].
However, it is important to remark the limitations ob-
served using MSCs to derive insulin producing cells.
First, C-peptide levels of differentiated cells were low
and unlikely to sustain normoglycemia in diabetic mice,
indicating the necessity to improve, qualitatively and
quantitatively, the insulin producing cell mass. On this
regard, the different germ layer derivation of MSCs
hinders the definition of differentiation protocols for
insulin producing cells [12, 47]. Furthermore, MSCs
clones display variable proliferation rates, which ham-
per the setting of standard protocols to obtain beta-
like cells [51–62].
Cellular therapy for type 1 diabetes with
embryonic stem cells
Among the variety of stem cell types, embryonic stem
cells (ESCs) retain the highest plasticity. ECSs can differ-
entiate to all body cell lineages and are uniquely capable
of indefinite self-renewal.
Applications of ES cells to human therapy began with
their characterization by Thomson et al. (1998) [13]. In
2001 Lumelsky et al. described what seemed to be a sim-
ple method to obtain insulin-producing beta cells from
human ESCs [64], although few years later it was dem-
onstrated that such method was generating neuroecto-
dermal cells instead of insulin-producing cells, with an
artifactual insulin release due to a hormone uptake from
the culture medium [65, 66]. Subsequently, several stud-
ies focused on discovering the ideal combination of fac-
tors for the derivation of definitive endoderm from
embryonic stem cells, marking the path for current pro-
tocols that represent the paradigm of ongoing pre-
clinical studies. In particular D’Amour et al. and Kroon
et al. defined in vitro stepwise pancreatic-induction pro-
tocols that recapitulated each phase of islet cells devel-
opment from embryonic stem cell to mature endoderm,
pancreatic progenitors and, finally, insulin producing
beta-cell like cells [67–69]. As a result, C-peptide and in-
sulin secretions were observed in cultures. In vivo exper-
iments on immunodeficient diabetic mices revealed that
normoglycemia was routinely obtained upon injection of
human ESCs-derived beta cells progenitors [70–72].
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Notably, the transplantation of ESCs-derived pancreatic
progenitors, rather than full differentiated ESCs-derived
beta cells, proved to be more effective in restoring
normoglycemia by means of the glucose-dependent re-
lease of insulin. Progenitor cells might retain a favoured
stemness profile for the in vivo maturation of functional
insulin-producing cells that could provide adequate
hyperglycemia responsiveness. The factors that allow the
efficient beta-cell differentiation in vivo are unknown,
but may include key elements that are difficult to repro-
duce in vitro, such as vascularization and interaction
with contiguous tissues [73].
However, the transplantation of a mixed population of
immature human ESC-(hESC)-derived cells is accom-
panied by serious safety concerns related to the persist-
ence of the tumorigenic risk. Current studies are being
addressed to solve the tumorigenic issues through the
sorting of the pancreatic progenitors from the rest of the
population [74] and antibody-based methods for the ab-
lation of tumorigenic cells [75].
An interesting alternative to ensure safety and
functionality of transplanted beta cell precursors and
hESCs-derived precursors, is represented by the use of
cell-encapsulation procedures. The enclosure of cells
within a barrier would allow diffusion of glucose, nutri-
ents, insulin and block larger molecules, cells and
antibodies. The physical selective barrier provided by
capsules could avoid the continuous subministration of
immunosuppressive drugs, thus ameliorating the quality
of life of diabetic patients. Additionally, the capsule
would protect the patient from any risk of tumorigen-
icity and allow the removal of the graft in case of mal-
functioning, increasing the recipient safety after
transplantation. Breakthrough studies have adopted en-
capsulation methods to transplant human beta cell pro-
genitors obtained from stem cells. Seung-Hee Lee et al.
transplanted human beta cell progenitors into a macro-
encapsulation device (TheraCyte), durable and biologic-
ally inert, which can be transplanted into human patient
for a year without adverse effects. The study demon-
strated the lasting survival, differentiation and function
of human beta cell progenitors in the device, with evi-
dence of cell replication and maturation. This approach
eventually resulted in the restoration of blood glucose
levels. In addition, the device provided protection from
allograft rejection for more than 140 days, suggesting
that encapsulated β-cells are invisible to the immune
system [76].
New frontiers: human amniotic epithelial cells
Placenta is the organ responsible for the correct foetal de-
velopment throughout all the phases of gestation, and is
considered a waste product of birth, but its tissues and
cells represent an abundant source of stem cells [77, 78].
Four regions of foetal placenta can be distinguished: amni-
otic epithelial, amniotic mesenchymal, chorionic mesen-
chymal and chorionic trophoblastic. Cells with variable
plasticity are isolated from each region: human amniotic
epithelial cells (hAEC), human amniotic mesenchymal
stromal cells (hAMSC), human chorionic mesenchymal
stromal cells (hCMSC), and human chorionic tropho-
blastic cells (hCTC). Among all the placental-derived cells,
hAECs and hAMSCs are both isolated from the amnion
foetal membrane. Various studies showed that hAECs ex-
press stem cell markers and retain the ability to differenti-
ate toward all three germ layers, therefore amnion have
been proposed as a biological source of stem cells for
regenerative medicine [79]. The advantages of using
placenta-derived cells can be resumed in the high and
worldwide availability of the samples, the non-invasive
procedures to collect and handle the tissue/cells, the
lack of any ethical issue related to the use of controver-
sial cells, and the low risk of graft-versus-host (GVDH)
diseases due to the immune privilege retain by placen-
tal tissues [80–83].
Moreover the transplantation of placenta-derived stem
cells for cellular therapy fully complies with safety require-
ments as there is no risk of tumorigenesis (teratomas)
[84]. In the last decade several promising studies have
been performed in animal and human trials, targeting
various diseases [85–90] including diabetes. Wei et al.
have shown that human amniotic epithelial cells from the
foetal part of the amnion after stimulation with Nicotina-
mide successfully express insulin mRNA in vitro and were
capable of normalizing the blood glucose level of
streptozotocin-induced diabetic mice for several weeks
after cells injection [91]. Recently Okere et al. showed the
in vitro development of hAECs 3D spheroids: “epi-
spheres” were then successfully induced into glucose-
responsive insulin producing cells [92]. Another report
showed a 7-days in vitro differentiation protocol to induce
hAECs into definitive endoderm, pancreatic foregut, pan-
creatic endoderm and, finally, pancreatic endocrine cells
[93]. The insulin producing cells derived from hAECs
were transplanted in STZ-rodents and after few weeks, a
significant and stable amelioration of glycaemia was
observed.
Conclusions
Despite the numerous and encouraging results presented
in the last decade, there is still a long road ahead to set a
reliable cellular therapy for diabetes. Scientists from all
over the world have to set their current and future stud-
ies on the basis of two major challenges of cellular ther-
apy: the safety and the efficiency of the transplanted
cells. Unfortunately, a cell source providing a robust re-
sponse after differentiation, is not always considered safe
because of transplant-related collateral effects such as
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immune rejection or, worse, tumorigenesis. Such chal-
lenges could be simplified by the adoption of totipotent
ESCs in opposition to adult stem cells. ESCs have the
greatest stemness potential, hence differentiation poten-
tial towards any lineage, any tissue and cell, but their use
raises concerns about safety and ethical issues. Although
the differentiation protocols have considerably improved
their efficiency the transplant of ESCs-derived cells is
still associated with the development of malignant tu-
mours due to incomplete differentiation of the clones.
Moreover, cells differentiation may lead to secretome
changes and phenotype alterations that can elicit the
host immune response compelling the patient to an im-
munosuppressive regimen. In order to bypass the re-
sponse from the immune system some researchers are
developing and testing various devices to encapsulate
the transplanted cells within a physical barrier, which
could allow the permeability to nutrients, glucose and
secreted hormones, and avoid contact with complex
molecules, cells and antibodies [76]. Despite hurdles
such as material’s biocompatibility, size and porosity, en-
capsulation systems showed encouraging outcomes with
the combination of a mild immunosuppression therapy,
which enhanced the functionality of the capsule and in-
creased survival of the transplanted cells within. Further-
more, culture of ESCs requires tools, equipment and
resources hardly affordable by most laboratories. The
use of the totipotent source is also hampered by ethical
issue since their use is forbidden by local jurisdictions in
several countries, including most European Nations. In
this scenario, a cell therapy based on ESCs-derived cells
will unlikely be worldwide available in the near future.
For this reasons an increasing number of scientists are
now focusing on different sources of stem cells that pos-
sess less stemness potential compared to ESCs but are
safer and free of ethical concerns, namely adult stem
cells. The pancreas itself is a promising source for stem
cells: duct cells, acinar cells and stem cell from islets of
Langerhans share the same embryological origin of beta
cells; therefore they are good candidates for the de-
differentiation and re-programming towards an insulin
producing phenotype. The obstacles to the extensive use
of this source are represented by the invasive collection
procedures, the scarcity of the stem cells, the difficulty
in isolating and expanding the culture in vitro.
The derivation of insulin producing cells from
hepatocytes (trans-differentiation or lateral re-
programming), which share with beta cells the same
endodermic origin, showed promising outcomes.
However, even though these tissues represent an
abundant pool of reprogrammable cells, the use of
hepatocytes ex vivo is hampered by the shortage of
donors, poor in vitro expansion capacities, and rapid
cell dedifferentiation [46].
Numerous studies described the use of MSC from
various tissues, pancreas included, as a widely accessible
source of insulin producing cells. The expectations on
MSC studies were nurtured by the abundance of cells,
the ease in isolation and in vitro expansion, and the
promising outcomes of various studies showing the dif-
ferentiation potential towards non-mesodermic lineages.
However, in vivo assays on animal models did not prove
to be as solid as in vitro experiments. In most cases
transplanted MSC-derived insulin-producing cells failed
to afford a stable amelioration in STZ-induced diabetic
mice. The controversy concerning in vivo potential for
MSC cells to differentiate into insulin producing cells is
supported by the postulated inability of mesodermic
cells to generate functional endocrine pancreatic cells,
which could be properly derived only from endodermic
progenitors. Further studies are required to improve the
in vitro pancreatic differentiation of MSC and conse-
quently a stable and responsive production of insulin
in vivo.
Therefore, scientists are continuously seeking for the
optimal characteristics of a stem cell source, which may
include: post-transplantation safety, wide availability,
non-invasive collection procedure, in vitro expandability
and differentiation efficiency. Stem cells isolated from
the amnion layer of placenta meet most of the men-
tioned criteria and the adoption of hAECs in cell therapy
and regenerative medicine do not raise any ethical
concern, unlike the use of ESCs which is restricted or
forbidden in most countries [92]. Further in vitro evalu-
ation will be necessary to define the therapeutic poten-
tial, but there is reason to be optimistic that a sufficient
number of efficient insulin producing cells will be avail-
able in the near future.
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